Friday, November 01, 2019 10:14:08 PM
Sponsor(s): Angionetics, Huapont Life Sciences (exclusive territorial distribution and license agreement for China)
Indication(s): Refractory angina (Phase III); Cardiac syndrome X (Phase I/II); Congestive heart failure (Phase I/II); Moyamoya disease (IND-enabling), Cerebral ischemia (Candidate selection)
Mechanism: Generx consists of the human fibroblast growth factor-4 (FGF-4) gene, a CMV promoter sequence, and a signal peptide, encapsulated in a human serotype 5 adenovirus. Generx is delivered to the heart using Angionetic’s optimized cardiac catheter technique, binds to heart cells via the coxsackie adenovirus receptors, and transfects the cells with the FGF-4 gene.
Trial(s) (Identifier): NCT02928094 (AFFIRM, Phase III)
Updates: NCT02928094 is expected to start June 1, 2019, with an estimated primary completion date of June 1, 2021. Angionetics is a majority-owned subsidiary of Gene Biotherapeutics (formerly Taxus Cardium Pharmaceuticals Group), but operates independently. Last year, Angionetics said it plans to externally finance clinical development and commercialization of Generx, which could include an initial public offering in 2019.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM